Terms: = Lymphoma AND CIITA, P33076, 4261, ENSG00000179583, MHC2TA, C2TA AND Treatment
12 results:
1. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Frontzek F; Ziepert M; Nickelsen M; Altmann B; Glass B; Haenel M; Truemper L; Held G; Bentz M; Borchmann P; Dreyling M; Viardot A; Kroschinsky FP; Metzner B; Staiger AM; Horn H; Ott G; Rosenwald A; Loeffler M; Lenz G; Schmitz N
Lancet Haematol; 2021 Apr; 8(4):e267-e277. PubMed ID: 33667420
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract] [Full Text] [Related]
3. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK
Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772
[TBL] [Abstract] [Full Text] [Related]
4. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract] [Full Text] [Related]
5. Structural genomic alterations in primary mediastinal large B-cell lymphoma.
Twa DD; Steidl C
Leuk Lymphoma; 2015; 56(8):2239-50. PubMed ID: 25393674
[TBL] [Abstract] [Full Text] [Related]
6. Histone deacetylase inhibitors activate ciita and MHC class II antigen expression in diffuse large B-cell lymphoma.
Cycon KA; Mulvaney K; Rimsza LM; Persky D; Murphy SP
Immunology; 2013 Oct; 140(2):259-72. PubMed ID: 23789844
[TBL] [Abstract] [Full Text] [Related]
7. Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.
Butler LM; Jeffery HC; Wheat RL; Long HM; Rae PC; Nash GB; Blackbourn DJ
J Virol; 2012 Jul; 86(13):7158-66. PubMed ID: 22532676
[TBL] [Abstract] [Full Text] [Related]
8. Defective class II transactivator expression in a B lymphoma cell line.
Prod'homme T; Drénou B; De Ruyffelaere C; Barbieri G; Wiszniewski W; Bastard C; Charron D; Alcaide-Loridan C
Leukemia; 2004 Apr; 18(4):832-40. PubMed ID: 14973505
[TBL] [Abstract] [Full Text] [Related]
9. Regulation of MHC class II expression in human T-cell malignancies.
Holling TM; Schooten E; Langerak AW; van den Elsen PJ
Blood; 2004 Feb; 103(4):1438-44. PubMed ID: 14563641
[TBL] [Abstract] [Full Text] [Related]
10. Lack of IFN-gamma-mediated induction of the class II transactivator (ciita) through promoter methylation is predominantly found in developmental tumor cell lines.
van der Stoep N; Biesta P; Quinten E; van den Elsen PJ
Int J Cancer; 2002 Feb; 97(4):501-7. PubMed ID: 11802213
[TBL] [Abstract] [Full Text] [Related]
11. Induction of ciita and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells.
Rigaud G; De Lerma Barbaro A; Nicolis M; Cestari T; Ramarli D; Riviera AP; Accolla RS
J Immunol; 1996 Jun; 156(11):4254-8. PubMed ID: 8666795
[TBL] [Abstract] [Full Text] [Related]
12. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.
Evans WE; Rodman JH; Relling MV; Petros WP; Stewart CF; Pui CH; Rivera GK
J Pharmacol Exp Ther; 1992 Jan; 260(1):71-7. PubMed ID: 1731053
[TBL] [Abstract] [Full Text] [Related]
